University of Birmingham - Cancer Research Clinical Trials Unit
Lucinda Billingham BSc MSc PhD CStat
Lucinda Billingham is Professor of Biostatistics within the Institute of Cancer and Genomic Sciences at the University of Birmingham. She has worked for over twenty years as a Biostatistician at their Cancer Research UK Clinical Trials Unit and is now Director of Biostatistics for the Unit working with a large team of Biostatisticians on an extensive portfolio of early and late phase trials. Lucinda has a special interest in lung cancer research and is the Chief Biostatistician for the National Lung Matrix Trial. She is a member of the British Thoracic Oncology Group Steering Committee and is an invited member of the Cancer Research UK Clinical Expert Review Panel providing statistical advice for funding applications. She lectures on a number of undergraduate and postgraduate courses at Birmingham, teaches widely on external courses and provides PhD supervision.
National Lung Matrix Trial: testing multiple novel targeted treatments
The National Lung Matrix Trial (NLMT) is a flagship trial in the United Kingdom being the first to combine the development of a technology platform that screens for multiple genetic aberrations in lung tumours (provided by the Cancer Research UK Stratified Medicine Programme) with testing of multiple novel genetic-marker-directed drugs. This presentation will summarise the challenges encountered with design, implementation and reporting of this umbrella-basket phase II platform trial.
EVEN MORE SEMINARS
Mr Hamish Clouston The Christie NHS Foundation Trust
Surgical Management of Advanced Colonic and Rectal Malignancies.
Professor Anthony Howell The University of Manchester / The Christie NHS Foundation Trust
Improving risk estimation of breast cancer
Professor Robert Thomas Bedford and Addenbrooke's Cambridge University Hospitals
Evidence based lifestyle strategies after cancer - a research review
Professor Noel Clarke The Christie and Salford Royal Hospitals, Manchester UK
Improving Prostate Cancer Outcomes Through Cancer Trials
Prof Ingunn Holen Department of Oncology and Metabolism, University of Sheffield, UK
Tumour cell dormancy and breast cancer relapse